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well as a more restricted life for people with disabilities. We examined the 
impact of US policy on reimbursement of intermittent catheters (ICs) on the 
lives of people with neurogenic bladder (NB) who require catheters to urinate. 
We conducted in-depth, longitudinal interviews with nine stakeholders. Actor-
Network Theory was used to describe interactions among human agents, IC 
products, and policies in the reimbursement arena. Restrictions on the type and 
quantities of ICs reimbursed emerged as the most potent inhibitor to health and 
wellbeing among consumers with NB. IC suppliers, due to the large number of 
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an impartial central clearinghouse on IC products and coverage impeded 
consumers’ ability to make informed decisions.  
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The individual (sometimes termed, “medical”) model of disability construes disability 
as lying within the individual and reflecting the consequence of physiological limitation 
whereas the social model of disability frames the locus of disability in the failure of society to 
provide appropriate services and assure that the needs of people with disabilities are taken into 
account in its institutions (Oliver, 1990). In US health reimbursement, the concept of medical 
necessity drives which products and services will be reimbursed (Palsbo & Kailes, 2006) but 
is not grounded in criteria endorsed at the broad societal (national) level (Bergthold, 1995). 
Reimbursement policies that interpret medical necessity inhibit the societal participation of 
people with disabilities and decrease well-being (Palsbo & Kailes, 2006). The purpose of this 
study is to explore how the process of reimbursing urological supplies in the US, specifically, 
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urinary catheters, shapes the urinary self-management of people with neurogenic bladder (NB) 
and influences their health and life choices. 
NB occurs when neurological damage or disease disrupts the normal urination process. 
People with NB urinate using urinary catheters, hollow, tubular devices inserted into the 
bladder through the urethra or a surgically-created stoma. Even when medical management is 
optimal, people with NB are at increased risk of life-threatening urinary tract infections (UTI) 
and renal complications (Dorsher & McIntosh, 2012; Manack et al., 2011). Up until the last 
quarter of the 20th century, renal failure and sepsis, consequences of impaired bladder 
emptying, were among the most common causes of morbidity and mortality in people with NB 
(Ginsberg, 2013). At least some degree of NB is common (over 80% prevalence) among people 
with spinal injury or disease (SCI/D; Taweel & Seyam, 2015). NB and related voiding 
pathology also occurs in virtually all individuals with spina bifida (SB; De Jong, Chrzan, Klijn, 
& Dik, 2008).  
In the 1960’s, a study involving newly injured persons with SCI showed that the 
technique of intermittent catheterization, inserting a catheter several times a day to remove 
urine, was associated with a lower rate of UTI than using an indwelling, continuously draining 
catheter (Guttmann & Frankel, 1966). Later, in the 1970’s, the use of clean, intermittent self-
catheterization (CIC) in those with SB (Lapides, Diokno, Silber, & Lowe, 2002) had a similar 
effect on UTI. In the almost 50 years since Lapides first introduced CIC, it remains the bladder-
emptying method of choice for people with NB (Lucas, 2019). Catheter technology has evolved 
however, and along with it the need for prescribers and payers to decide which features are 
medically necessary for which individuals (Lamin & Newman, 2016), effectively shaping the 
options of people with NB relative to bladder management and how they structure their lives 
around it. 
In an earlier study, we identified the range of urinary symptoms experienced by people 
with SCI and SB who use ICs (Tractenberg, Garver, Ljungberg, Schladen, & Groah, 2017). 
We observed that individuals manage urinary symptoms, in keeping with clinical consensus 
(Lukacz et al., 2011), by increasing fluid intake, leading to increased catheterizations and, as a 
consequence start to deplete their catheter supply. In the US, ICs are a specific class of 
urological product, provided monthly, in capped quantities, through public and private health 
insurance programs. Since emptying one’s bladder is not optional, fear of running out of ICs 
led to behavior that put individuals at risk for redoubled infection -- reuse of inadequately 
disinfected ICs (Avery et al., 2018) -- or decreased social participation, particularly among 
women who have run out of ICs suitable for use in public toileting facilities. 
The picture of the IC that emerges from the literature is one of a technology that has 
evolved to address the health of people with NB holistically, supporting both physiological and 
psychosocial wellbeing.  However, the contemporary US health care system, through its 
reimbursement policies, conceives the fit of an individual IC product to the person who relies 
on it more narrowly, typically (though not always) endorsing the minimally appropriate system 
that safely supports the strictly physiological function of urination. There is no central 
information clearinghouse that individuals with NB can consult to understand which insurers 
offer which IC options, under what circumstances and at what cost. This lack of clarity makes 
it extremely difficult for people to take charge of their bladder health and navigate their way to 
an IC solution that is optimizes their personal needs.  
Our interest in conducting this study was to better understand the patterns of resourcing 
that people with NB use to get their ICs and the barriers and facilitators they encounter. We 
wanted to get high-level insight into how resourcing took place, who was involved, and how 
strategies modulated in response to changing circumstances.  A focus of our group’s research 
over the past six years (see Support) has been to identity the priorities of people with NB with 
respect to urinary outcomes, criteria they identify as important to their quality of life in 
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managing urinary function versus the strictly medical priorities that may be reflected by the 
health care system. We have personally observed how health care policy, which IC 
technologies are paid for and by whom, influences individuals’ decision making around how 
they manage their bladders which, in turn, is reflected in their decision making relative to life 
goals and how they will participate in society.  
The interests of authors on this manuscript vary, but coalesce in our deep concern for 
optimizing the wellbeing of and opportunities available to people with NB. MMS, is a 
technology researcher with a specific interest in how people use technology to enhance their 
function, particularly in the context of disability. She has functioned as the qualitative methods 
lead for our group. AKR is a rehabilitation researcher who has been extensively involved in 
field research related to bladder management among people with NB who experience a wide 
variety of levels of voiding impairment.  TMcM is an individual with SCI well-versed in the 
science of neurological impairment. He has worked with us extensively since 2014 in 
conducting and analyzing interviews and focus groups involving people with NB. AB and HC 
are disability policy experts who have, likewise, been members of our patient-centered 
outcomes research team since its inception. HC, additionally, is an individual who himself has 
an SCI. SLG is a physician SCI researcher who served as the director of the grant (see Support) 




Overall Approach: Use of an Actor-Network Theory Framework 
 
We used an Actor-Network Theory (ANT) conceptual framework (Latour, 2005) to 
explore the interplay of persons, organizations, policies, and technologies that make up the IC 
reimbursement ecosystem in the US.  ANT is distinguished by its treatment of human and non-
human actors - people, things, and abstractions - as all exerting influence, creating push and 
pull, in the networks in which they act. We adapted the phases of ANT analysis described by 
Carroll and colleagues (Carroll, Richardson, & Whelan, 2012) to the specific, healthcare 
reimbursement context of our study. See Table 1.  
 
Table 1 
Actor-Network Theory (ANT) Phases 
 
ANT Phase Description 
I. Identify the stakeholders Identify the human (people, capable of volitional acts) and non-human 
(ex. rules, technologies, money) actants who influence or are influenced 
by one another in catheter reimbursement. 
II. Investigate the stakeholders Examine the experiences and perspectives of human stakeholders through 
interviews and review of the documents they provide. 
III. Identify stakeholder interactions Trace interactions among stakeholders to explore how they influence one 
another. 
IV. Construct an actor-network model Visualize such aspects of the network as convergence and distribution. 
V. Identify inhibitors and enablers Determine who/what enables and inhibits actions in the network. 
VI. Examine irreversibility Determine to what degree it would be difficult to make a change. 
Adapted from the analytic paradigm (McBride, 2000) as summarized by Carroll, 2012, p. 60. 
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Research Questions 
 
Aligned with the ANT perspective, the following research questions guided our inquiry: 
 
1. What does the US intermittent catheter (IC) reimbursement network look like? 
2. What are the inhibitors and enablers in the network ecosystem that impact bladder 
management practices, health, and quality of life among people with neurogenic 
bladder (NB)? 
 
ANT Phase I: Identify the Stakeholders 
 
Recruitment and Participants 
 
We purposively recruited consumers1 with NB and varying types of health insurance 
plans, public and private, to explore their experience of IC reimbursement. We conducted in-
depth, semi-structured interviews using a guide (available at 
https://1drv.ms/b/s!AnAG82yv9Ycphc8A-32B8S4fF5zTxg?e=wZCy1L) adapted from an 
instrument previously developed by our research group for use in focus groups involving 
people with NB who used ICs for bladder management (Tractenberg et al., 2017). We chose 
the semi-structured interview format to make sure we asked all of our pre-determined questions 
while at the same time keeping the process sufficiently open-ended to capture the breadth of 
people’s IC reimbursement experience we had glimpsed in our prior work with people with 
NB.  
Our initial consumer participants identified other stakeholders in the reimbursement 
process whose interactions strongly impacted their access to catheters. We subsequently 
recruited a physician, a representative of a catheter supplier/distributor, a catheter manufacturer 
representative and a disability advocate, to triangulate information and sharpen the picture of 
catheter reimbursement.  A total of nine individuals participated in interviews2 (see Table 2). 
Six were consumers: four with NB and SCI and two caregivers (parents) of minors with NB 
and SB. Two participants brought a dual perspective to their interviews. One individual with 
SCI and NB worked as a nurse practitioner with patients with NB. The catheter supplier product 
and service specialist was, in addition, the mother of a child SB and NB. See Table 2. 
 
Table 2 




Sex  Role(s) 
Catheter Use Profile Catheter Coverage 
Type Rx Amount Primary Secondary 
Amy F Consumer, SCI Closed 6/day Private Commercial None 
Beatrice F Consumer, SCI Straight  







Chuck M Consumer, SCI; 
Nurse Practitioner 





Don M Consumer, SCI Hydrophilic 8/day VHA None 
 
1 We believe the term “consumer” is a better fit than “patient” in describing our participants with NB/caregivers 
as the focus is on reimbursement of a commodity that is consumed and replenished, the IC. 
2 The study was approved and supervised by the MedStar Health Institutional Review Board, Washington, DC 
USA.  
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ID 
 
Sex  Role(s) 
Catheter Use Profile Catheter Coverage 
Type Rx Amount Primary Secondary 
Ellen F  Mother of male 
child with SB 
Hydrophilic & 
Closed (50:50) 
6/day Private Commercial Medicaid (Public, 
administered by 
individual states) 
Fran F Mother of male teen 
with SB; Supplier 
Hydrophilic 5/day Private Commercial Medicaid  
Gillian F SCI Specialist 
(Physician) 
 
Hank M Manufacturer 
Iris F Disability Advocate 
 




Given that our participants were geographically dispersed around the US, all interviews 
were conducted by phone. We used a professional service to record all calls; the same service 
also provided smooth verbatim transcripts of each interview. The person conducting an 
interview was also the individual who verified its transcript. Interview data were captured at 
two time points. The first round of semi-structured interviews, 19.0 to 66.8 minutes in length 
(mean = 43.6), were with all nine participants.  After completing our preliminary analysis, we 
re-engaged seven of the nine participants in follow-up interviews. These follow-up interviews, 
24.5 and 91.1 minutes (mean = 46.4) in length, took place from 9.4 to 13.8 months after initial 
interviews. The purpose of re-engaging participants was to share and verify (member-check) 
our initial understanding of IC reimbursement, and gage, longitudinally, how individuals’ 
experiences or perspectives might have changed since our initial conversations. We followed 
up with the remaining two individuals whom we did not formally re-interview, via e-mail.  
Transcripts were uploaded to a cloud-based qualitative data analysis application, 
Dedoose (SocioCultural Research Consultants, 2018), to facilitate collaborative analysis. 
Explanation of Benefits statements shared by consumers and catheter policy-focused 
documents provided by the disability advocate were also managed centrally using Dedoose. 
Our general impression was that all participants we spoke with were extremely forthcoming. 
The phone versus face-to-face communication medium for discussing a topic as personal as 




We followed an Interpretative Phenomenological Analytic (Smith, Flowers, & Larkin, 
2009) approach in identifying themes in and across interviews. We chose to use an 
interpretative phenomenological analytic (IPA; Smith et al., 2009) approach to making sense 
of our data for two reasons. First, a network as conceived within ANT theory, is a phenomenon 
in continual flux that we set out to understand through our participants’ interactions with it. 
Second, IPA provides a thorough, stepwise process for evaluating each case on its own merits 
before intermingling themes with those coming from a different case. 
For each individual participant, we began by reading and rereading the transcripts (re-
listening to audio recordings for tone if there was a question of emotional charge or irony), 
creating initial memos and assigning open codes, to borrow terminology from grounded theory 
(Strauss & Corbin, 1998) to identify emerging themes. Disagreements about interpretation 
were resolved by discussion and consensus. We subsequently noted connections across themes 
within an individual interview and repeated the process for each successive interview. 
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We began to identify links across participants as soon as the initial analysis of the first 
two interviews was complete, exploring whether emerging phenomena inhibited or enabled the 
appropriate acquisition and use of ICs by people with NB. We iterated this process, expanding 
and refining our framing of cross-cutting themes until each interview was considered in light 
of the others. We sketched out a preliminary model of actor-network relationships and went 
back to our stakeholders for the second round of interviews to clarify and expand on 




RQ1. What does the US intermittent catheter (IC) reimbursement network look like? 
 
ANT Phase III: Construct an Actor-Network Model 
 
The actor-network model (Figure 1) provides a picture of the interrelationship of people 
and components in the overall process of catheter reimbursement via experiences of the 
stakeholders we interviewed.  Labeled actor-nodes had an interaction count of five or greater 
with other actor-nodes. These interactions and more peripheral ones are described below. The 
supplier interacted with the largest number of other actors in network, followed by the 
consumer and the private insurer.  
 
Figure 1 
US Intermittent Catheter Actor Network. Connectivity Among Human and Non-Human 
Actors. Labeled nodes have a degree of 5 or greater (range, 2-14), showing suppliers, 
consumers, and private insurers as the most “connected.” Constructed using Gephi v. 0.92 
(Bastian, Heymann, & Jacomy, 2009). 
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RQ2. What are the inhibitors and enablers in the network ecosystem that impact bladder 
management practices, health, and quality of life among people with neurogenic bladder (NB)? 
 
ANT Phase IV: Source of Inhibitors and Enablers 
 
The catheter reimbursement network described by stakeholders contained both 
inhibitors and enablers of people’s optimum acquisition of ICs. Perceived narrow 
reimbursement rules and procedural burden inhibited people with NB to get the ICs they felt 
most appropriate to their bodies and lifestyles. This burden interfered with their ability to 
receive sufficient quantities to assure their ability to empty their bladders, whatever 
contingency life might bring. The catheter supplier emerged as the reimbursement network 
enabler, the actor in the right position to get the consumer the most appropriate IC, in a timely 
fashion, at a satisfactory price. 
 
Few Reimbursement Codes, Many IC Varieties 
 
CMS sets the rules that drive catheter acquisition: which consumers (based on medical 
criteria) can receive reimbursement for type of catheters, what cost, and quantities. Three 
categories of intermittent catheters are recognized -- straight, coudé (curved), and sterile kit 
(“closed”) -- and all products are required to meet the criteria of, one of these three types to be 
reimbursed (see Table 3).  
 












200/month Pre-lubricated with touch-free, “gripper” insertion mechanism. 
Reimbursed as a straight IC, but typically exceeds the 
reimbursable amount. Some payers, such as VA, will cover if 
medical necessity, such as recurrent UTI, documented by a 
physician 
A43523 Coudé (curved) 
Catheter 
200/month Includes one individual packet of lubricant per catheter. A 




Catheter Kit (aka 
Closed Catheter) 
200/month Most expensive IC. Comes with gloves and other equipment to 
perform sterile IC. Requires physician documentation of two 
UTI within the past year meeting stringent quantitative 
criteria. Exceptions include being a resident of a nursing 
home, immunosuppressed, a pregnant woman with SCI, or 
having radiologically verified vesico-ureteral reflux. 
 
Source: Noridian Health Care Solutions, LLC. Local Coverage Determination (LCD): Urological Supplies 
(L33803) 
https://med.noridianmedicare.com/documents/2230703/7218263/Urological+Supplies+LCD/3aeb7caa-2773-
4c83-acdc-758d245fd643. Updated 10/9/2020, retrieved 10/23/2020. 
 
3 None of our consumers had used coudé catheters, nor did they figure prominently in the experiences related by 
our catheter industry informants or disability advocate. They are listed here for completeness, but don’t figure in 
the article itself, as a result. 
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CMS pays one price for any product within the specified code regardless of quality within 
product codes. Accordingly, consumers whose insurance, for instance, Medicare, only pays on 
the CMS fee schedule are constrained to pick a catheter at or under the CMS price point. 
Increasing consumer options was identified as a concern by Iris, the disability advocate: 
“Looking at the Medicare space as a whole, and looking at the health reform space as a whole, 
we are constantly pushing for variety of products in plans.” 
Contrary to the impression created by reimbursement codes, ICs are a technology under 
continual evolution, manufactured in a variety of materials, sizes, incorporating features to 
reduce risk of infection during cathing as well as to enhance user comfort, convenience, and 
the overall esthetics of catheters. Fran, the catheter supplier and mother of a teen with SB, 
described the surprised reaction she encounters at product expos. “When somebody comes to 
my table and they see that there are 30 different kinds of catheters, they’re like, “I didn’t even 
know there were all of those out there!”  
Within each of the categories CMS uses for IC classification and reimbursement (see 
Table 3), manufacturers work to attract consumers to their products by focusing on the 
subjective experience of cathing people with NB encounter in everyday life, as Fran’s 
description of her typical interaction with potential clients at product expos suggests. 
Manufacturers compete to differentiate their IC products by offering a wide range of designs 
and price points. Areas of focus include enhancing the individual's personal and social comfort 
with the IC through discrete and attractive packaging, promoting convenience in preparing the 
IC for insertion, and addressing the comfort and efficiency of cathing by taking into account 
such individual differences as limited hand function, body mass, and agility. Disposability, 
both immediately after use or at a later time as may be more appropriate in certain context such 
as visiting friends, is a further product differentiator focused on designs to augment the 
wellbeing of the whole person.  
 
Private Insurance and Coverage Uncertainty 
 
Private payers also use the three-tiered coding system established by CMS for the three 
categories of catheters. However, they retain autonomy to determine the terms of the coverage 
they offer, particularly in plans they negotiate with large employers who, in turn, offer these 
products as part of their employee benefits package.  The business relationship established 
between the insurer and the employer around the contract is an enabling condition. The creates 
an opportunity for discretionary action if the employer chooses to intervene on the employee’s 
behalf with the private insurer. Ellen related how she enlisted her employer’s greater leverage 
with the payer for her son with SB. “When we ran into issues getting coverage, I reached out 
to the head of Human Resources and had her call the insurance company, and got it straightened 
out.” 
Fran, the supplier, however, explained that she could never tell a client with private 
insurance what coverage was available for a given catheter product until her office “ran their 
insurance.” Two consumers with the same private payer but different employers are likely to 
have different coverage under the different plans sold to their different employers. Amy, a 
woman with SCI, described her difficulty in calculating her actual out-of-pocket expense for 
catheters when she switched to a new, nominally less expensive plan offered by her company. 
 
My catheters were covered last year, but I changed to a different plan. It's a 
high deductible plan, cheaper each month, [but my catheters] are not covered. 
March was the first time that that claim [e.g., for catheters] was submitted 
under the new plan. So, on my Explanation of Benefits, where you see like a 
balance of $2,000 for catheters, I have yet to receive anything [a bill] from 
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[supplier.]  We’ll see at the end of the year if it actually was cheaper, depending 
on out-of-pocket [expenses]. (Amy) 
 
The Explanation of Benefits (EOB) Amy references is the usual way US health insurers, 
both public and private, communicate to their policy holders about health products and services 
they have agreed or declined to reimburse. The EOB is retrospective; the service or product 
provider will typically submit a claim for reimbursement and the insurer will agree or decline 
to pay. If the insurer declines, the consumer is responsible for making the payment personally. 
The provider is expected to follow up with a bill to the consumer. What services and products 
consumers can expect to be covered by insurance and what their own out-of-pocket 
responsibility will be varies based on the terms of the specific plan elected. Individuals know 
broadly what their insurance will and will not pay for when they sign up for coverage. However, 
specific determinations are made when a claim is received. Appeal is possible and negative 
determinations can be reversed. The onus of appeal is on the consumer. Table 4 shows the 
components of a typical EOB provided to policy holders. 
 
Table 4 
Typical Explanation of Benefits Components 
 
Component Description 
Patient details Identifies the beneficiary, the person who received (or was denied) the 
insurance benefit  
Medical services Services (and products) received by the beneficiary and from whom, that 
is, services for which a claim was filed and processed 
Amount billed Cost of the services for which a claim was file 
Discounts Any money the beneficiary may have saved by accessing care or medical 
products from within the individual plan’s network of providers, that is, 
providers with whom the plan has a special contract 
Amount paid  The portion of the amount billed that the insurer paid 
Amount not covered The portion of the amount billed that the insurer did not pay 
Other payments that 
may have been made 
Some expenses not covered by insurance may be reimbursed to individuals 
through special, tax-preferential accounts (Health Savings Accounts and 
Other Tax-Favored Health Plans, 2020) they have established such as a 
health reimbursement account (HRA) or flexible spending account (FSA). 
Amount outstanding Any outstanding amount the beneficiary is responsible for paying 
Terms and definitions A glossary of the terms and definitions included in the EOB, as well as 
instructions for how beneficiaries can appeal a claim, if necessary 
Specific details More specific details about the cost of the services/products that the 
beneficiary received 
  
Catheters Over-the-Counter  
 
Coverage uncertainty impeded one’s ability to plan but being able to purchase basic, 
uncoated, single-use, straight catheters over-the-counter (OTC) at certain retail outlets enabled 
consumers, at a minimum, to assure they always had a backup cathing plan.  The question of 
which jurisdictions permitted sale of ICs without a prescription was equivocal. Consumers with 
SCI (adults) uniformly reported on the widespread reliance and availability of uncoated basic 
ICs as proof against failing to receive their regular, payer-reimbursed supply, of whatever type. 
Amy described her successful and unsuccessful efforts to get a stop-gap supply of straight 
catheters when there was a delay in receiving the closed catheter systems she regularly used.  
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You have to cath! Right? I have gone to a local [well-known retail pharmacy] 
that has a pretty good medical supply, and they have had catheters behind the 
counter.  And they told me, “No, you need a prescription for this.” Then, I go 
to the regular medical supply store and they're like, “Oh, yeah.  What size do 
you need? (Amy) 
 
“You have to cath” identifies the central problem created by ambiguous policy 
governing direct-to-consumer sale of minimal, basic ICs. Missing even a day of cathing is 
health threatening. Amy’s resourcefulness got her what she needed, but at a high cost relative 
to life disruption. The medical supply store she refers to is 45 minutes to an hour from her home 
and open 9-5 in contrast to the extended hours her neighborhood retail pharmacy provides for 
shopper convenience.  Amy had to take leave from work to get to the medical supply store 
during business hours. She also had to arrange special transportation. Like many people with 
SCI, Amy does not drive. These efforts were absolutely necessary, however, to make sure Amy 




Basic uncoated catheters, available OTC, do not meet the needs of all people with NB. 
Hydrophilic catheters (HCs) are a more recently developed (and typically more expensive) 
product that has a slick coating and inserts touch-free with a gripper. These characteristics may 
provide a sanitary advantage over uncoated catheters to which the consumer (optionally) 
applies a lubricant. An increasing number of studies report a lower incidence of UTI in people 
using hydrophilic versus uncoated catheters (Clark et al., 2016; Rognoni & Tarricone, 2017; 
Truzzi, Teich, & Pepe, 2018; Watanabe et al., 2017; Welk, Isaranuwatchai, Krassioukov, 
Husted Torp, & Elterman, 2018). The more expensive-to-produce HC is coded the same, and 
reimbursed the same, as the less expensive uncoated straight IC, resulting in an impediment to 
access (See Table 3). Payers, outside of Medicare, may optionally cover the higher cost of HCs. 
However, this demonstration of need is based not on preventing, but on addressing a problem 
of recurrent UTI. Don, a veteran with SCI who wanted to take advantage of the health benefits 
associated with HCs, described the difficulty he had in persuading the Veterans Health 
Administration (VHA – colloquially, simply VA) of the legitimacy of his goal. 
 
You keep trying to figure out what the statement is that they need to hear for 
you to get the type of prescription that you need.   I’m telling the VA I want 
hydrophilic, and they’re saying, “You don’t.” -- that saying you WANT 
something, isn’t enough.  You want something because of its benefit. So, for me 
to get the hydrophilic, because it wasn’t a standard issue, I had to explain that 
I was getting bladder infections that were exacerbated, if that’s the right word. 
[pause] Irritation from a non-hydrophilic catheter. (Don) 
 
VA is a national, self-insured health service provider and has a reputation for liberality 
in extending benefits to veterans. Don’s experience demonstrates that despite its liberal stance, 
VA wanted to hear that the hydrophilic catheter was needed to remediate injury that 
purportedly caused UTI. That the literature suggests a preventive benefit was not deemed 
adequate reason for the prescription of an HC. Our disability advocate, Iris, expressed 
frustration over the lag in access to products this perspective creates in the US, that is not 
suffered by people with NB in other countries. 
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[Hydrophilic,] that’s an ongoing issue, right? I mean, it’s supposedly a new 
technology that’s been around for what? 10 years at least!  And these problems 
aren’t the same in the European space, but in the US space, there have been 
various companies -- manufacturers that have requested an additional 
component for hydrophilic catheters. (Iris) 
 
Manufacturers argue that HCs are a class of products different from uncoated straight 
ICs (Centers for Medicare and Medicaid Services, 2014).  However, CMS has not, as of this 
writing, recognized an essential difference between coated and uncoated products. As a result, 
the expense of a coated product is only supported when the more basic, uncoated product, 
results in demonstrable harm (UTI). 
 
“Closed,” Sterile Catheter Kits 
 
CMS addresses the issue of UTI in its criteria for reimbursement of a sterile (commonly 
termed, “closed” or “all in one”) catheter kit. The way the system is designed, the consumer or 
caregiver never touches the catheter during insertion and, after cathing, the entire unit – 
catheter, bag, insertion supplies and urine - can be discarded. Closed catheters are the most 
expensive type of IC. The bar is correspondingly high for closed catheter reimbursement 
requiring an individual to have two, physician-documented UTI, meeting highly specific, 
defining criteria (see Table 3), within the period of a year. Withholding an infection reducing 
IC until a person with NB, already vulnerable to UTI (DeJong et al., 2013; Dicianno & Wilson, 
2010), suffers two severe infections impedes that individual’s ability to prevent UTI.  Iris, 
disability advocate, pointed out the dissonance between policy that repeatedly exposes people 
with NB to needing courses of antibiotics to fight UTI and the general population healthcare 
perspective on limiting antibiotic use. 
 
It’s not safe healthcare policy to put vulnerable individuals in the face of having 
to deal with more UTIs! We’re trying to limit exposure to unnecessary medicine; 
if you have to take antibiotics enough times, you become resistant. It can be 
fatal if antibiotics no longer work and you can end up in a hospital with more 
severe medical conditions.  (Iris) 
 
In the US, the general population policy trend toward greater support for preventive 
practices, such as the antibiotic stewardship those designed to mitigate the danger of antibiotic 
resistance that so concerns Iris, does have a parallel in policies applied to people with chronic 
conditions such as NB.  
In the US, disease prevention policies, such as the promotion of antibiotic stewardship 
to which Iris alludes, do not explicitly recognize the risks accompanying reliance on urinary 
catheters for voiding. The Antibiotics Aware program promulgated by the US Centers for 
Disease Control and Prevention (CDC) focuses on treatment of infection once acquired and 
does not explicitly consider infection routes such as IC (CDC, 2019). Notably, in its guidelines 
for prevention of catheter-associated UTI, the CDC affirms that there is some evidence to 
support the role of HC in infection prevention (Gould et al., 2009). 
 
Catheters as Enablers of Community Participation 
 
Without a closed system, women with NB can face cleanliness challenges cathing when 
away from home. Fran shared her female clients’ concern about public restrooms. 
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Men can urinate into a urinal.  Women have to go into the stall. It doesn’t matter 
if they washed their hands before they got onto the toilet, they have touched 
everything in the place. So by giving them closed bags it – even if they have to 
go into a stall -- it just eliminates a lot of the germs. (Fran) 
 
Apart from sanitation, toilet accessibility was another source of impediment. Amy 
described the life disruption she experienced when she ran out of closed catheters. 
 
So, where I usually can cath from my chair with the bag, with these catheters 
that I get from the medical supply store, I have to transfer to the toilet and cath 
into the toilet --which at home is fine, but sometimes out in public, it’s not 
feasible. So I do plan. Ok, if I’m going to go somewhere, can I access the 
bathroom because of this straight cath? Otherwise, with the closed system, if I 
can get into a private space with a closed door, then I can go ahead and do 
what I need to do. (Amy) 
 
The closed catheter was also identified as enabling a young child’s developing 
competence in self-cathing. Ellen noted, “For my son, especially teaching him to self-cath, 
there’s one closed system that he can use easily, and we would go through A LOT to make sure 
he gets the system that he’s independent with.” 
Drawing on her experience with client product requests, Fran described a scenario of 
catheter provision fit to the life needs of an individual. 
 
A spinal injury person who plays Quad Rugby for example, when they’re at 
home, they actually want a straight catheter, no bag, so that they can urinate 
into their adjusted bathroom, that’s been modified for them. When they are not 
in that ONE bathroom in the entire world, they want a catheter that they don’t 
have to touch, that they can insert with one hand, and so they want a [brand 
name] compact set because it’s nice and soft and it comes with a bag, and they 
can take care of their needs all by themselves, without anybody else.  But when 
they’re playing Quad Rugby, or possibly even just every day when they are in 
between cathing, they want a condom cath4 on and a little bag on their thigh to 
leak into, so that they can catch the dribble so that their pants, that their 
wheelchair, and ultimately the floor, isn’t being covered in urine. (Fran) 
 
The experiences described above show the range of concerns that people with NB have 
with respect to how they cath. The theme that distills from them all is the social importance of 
urinary management. It is a hallmark of the transition to adulthood as Ellen’s deep concern for 
her young son’s ability to self-manage demonstrates. Concerns about how urination will be 
managed shapes decision making about how and the degree to which one will participate in 
adult public life as Amy and Fran describe. 
 
Not Having Enough Catheters 
 
Payers’ rules allocate catheters to consumers on a monthly basis and providers are 
subject to audit (and denial of payment) if violations are found. CMS limits ICs to 200 per 
month. According to Iris, Medicaid, in some states, provides even fewer. She noted, “We’ve 
 
4 A different type of catheter entirely, not intermittent 
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actually been active in working at the state level in pushing the 200 limit or at least making it 
a 200 limit to match the Medicare requirement at the state level.” 
The IC cap was an impediment addressed by consumer planning; all consumers had 
contingency plans to address delayed shipments, lost or damaged products, or accelerated 
catheter “burn” rates. Chuck, a Veteran with SCI and a nurse practitioner working with people 
with NB, confided that he has an emergency supply of catheters courtesy of an initial 
(undetected) double shipment.  
 
I had gotten a double supply at one point.  So, I've been able to continue with 
that cushion for a long time. I probably have a good couple of months supply. 
That cushion helps because, once you miss one delivery, you’re getting into 
down to the quick, and we try to avoid that. (Chuck)   
 
Amy and Don experienced that being active in athletics was a common reason for using 
catheters at a higher than planned rate.  Amy described the impact of swimming on her usual 
catheter consumption of six per day and her strategy for compensating. 
 
When I’m swimming a lot, I have to cath more. So sometimes when I swim for 
two hours, I have to cath three times within that period. When I’m swimming 
four or five days a week, I run through a lot more catheters than I usually would. 
So then sometimes I will try to go longer between cathing:  instead of four hours, 
five hours. Then maybe I have to run to the medical supply store to cover the 
next two or three days. (Amy) 
 
Notably, Don had negotiated an exception to the 200/month cap with VA; his 
prescription provided him eight per day, approximately 240/month. In the case of Beatrice, 
who was in the habit of supplementing her 90/month IC prescription with OTC catheters, a 
natural disaster threatened her catheter security. She told of a stress-filled five days trapped in 
her apartment with a dwindling supply of IC. 
 
During Hurricane Sandy, for some reason, I was having -, probably from stress- 
just so much trouble using the short catheters!  I was going through like dozens. 
I was in the bathroom with a flashlight [trying to see to cath].  I went through 
quite a few of them, just because I just couldn't, couldn't get it in! (Beatrice) 
 
Our informants demonstrate that fluctuations in life happen to people with NB just as 
they do in the general population. Choosing to increase participation in a sport, as Amy related, 
or being forced to cope with a natural emergency, as Beatrice described, both resulted in an 
unforeseen uptick in their rate of IC utilization. Certain medications may be prescribed PRN, 
use as needed. This concept does not extend to ICs, though experience shows that consumption 
is not static. 
 
The Catheter Supplier as Network Enabler 
 
The IC reimbursement network diagram (Figure 1) shows a cluster of activity inputs 
and outputs (14) placing the supplier at the center of the key transactions of product selection, 
payment negotiation, documentation, and fulfillment that take place across the network to 
accomplish the end result of getting catheters into the hands of consumers. In the VA system, 
fulfillment is centralized and the veteran/consumer rarely interacts with the supplier(s) with 
whom the VA contracts. On the contrary, in the case of our consumers with private or Medicare 
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insurance where the supplier is a highly visible, all reported highly positive relationships with 
their catheter suppliers. In Amy’s case, she declined to leave her long-time supplier when she 
switched insurance even though she was told the supplier would be out-of-network and her 
cost for catheters undetermined.  Amy explained her trust and loyalty to her supplier. 
 
I have been with [supplier name] for years now. They're really great and I have 
a great relationship with them. The care coordinator that I work with told me 
that what I see on my EOB [under her new policy] will not be what will be 
billed. [But now] that amount of $2,000 on my EOB, it does concern me! [But I 
was also concerned, if I left my provider] that I wouldn't be able to get the 
catheters that I need and that I REALLY like to use  -- and have that convenience 
of them being shipped to my house each month. So I’m just kind of going with 
it, because I do like the product and the service. (Amy) 
 
Our stakeholders identified responsiveness, product knowledge, timeliness, supply 
security, and ease of transaction, as being suppliers’ key enabler characteristics. These traits 
also emerge from the perspective of the physician, Gillian, on the consumer-supplier bond. 
 
It's very important to them [people with NB], that they've got a good system set 
up, and that they don't want to do anything to mess it up. If the distributor is, 
yes, responsive and gets them their catheters -- whether it's right or not-- in a 
timely fashion, and they never run out, and there's never a problem and it's easy, 
that patient’s gonna stick with them because they DON’T want to get stuck 
without a catheter. (Gillian) 
 
The importance of product knowledge, as Gillian implied, an IC is most appropriate for 
a given individual, is perceived differently by those on the providing side (manufacturer, 
supplier) and those on the receiving side (consumers). Hank, the manufacturing stakeholder, 
valued suppliers’ ability, by virtue of their position between product and consumer, to get new 
improved products into the market and in use. From his perspective, product knowledge was 
an important differentiator among suppliers. He provided a retail merchandise analogy. 
 
We spend a lot of time [in product education] at the provider [supplier] level. 
Let’s say you’re going to go shopping and you have to decide whether you go 
to Target, Kmart, or another store.  They all really are going to have 
fundamentally the same products, right?  So then how do they differentiate 
themselves? They can offer to give you a better product, they can offer you a 
bigger selection, they can offer you samples so that you can try different things. 
(Hank) 
 
The consumer perspective on the value of the supplier’s ability to bring product 
diversity, particularly the value of sampling, was more reserved. Ellen, particularly, had not 
experienced her supplier’s understanding of product range and knowledge for product 
appropriateness for a developing child with SB. 
 
I don’t know if they [suppliers] are as attuned to subtle differences, which 
different closed systems are easier for a seven-year-old boy to use than others. 
It's more like, okay, there’s a bunch of different things.  Figure out which one 
is going to work best. (Ellen) 
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Consonant with the physician’s observation of a relatively low threshold for catheter 
satisfaction, Beatrice affirmed her confidence in her supplier but at the same time described 
her lack of interest in supplier’s efforts to expose/interest her to new technologies.  
 
I'm not a big catheter explorer, so I tend to stick with what I’ve been using for 
years.  I know there’re a lot of options out there now.  [My supplier is] very 
open, “Hey, if you need any other kind of catheters, we can get those for you.” 
They really work on behalf of the patient, such as myself.  I’ve used one or two 
that have been sent to me as free samples from [supplier], but I have specific 
catheters that I use and stick with them. (Beatrice)  
 
On the other hand, Ellen told of attending product expos and Amy was an avid follower 
of manufacturer’s product updates. She discovered, for example, that her ICs contained DEHP, 
a plasticizer with teratogenic properties, and she changed to a different product.  
Beyond product selection, the supplier removed most burden from the consumer, 
managing everything from claims paperwork to getting catheters to the doorstep.  
 
When we switched to a new insurance company, there was some leg work 
involved making sure that the new insurance company had everything that they 
needed. Our supplier, for the most part, took care of that.  I have to say that 
they’ve been great about shipping times. Last week, I placed an order on 
Wednesday, and the box was here on Friday. Then in August, we were at the 
beach and it was the week that [my child] needed his supply, so they just 
changed the delivery destination to the place where we were! (Ellen) 
 
Finally, consumer out-of-pocket cost minimization emerged among the supplier 
practices consumers most appreciated. In the case of Amy, who elected to stay with her 
supplier, with uncertainty how it would affect catheter cost, her out-of-pocket expense ended 
up being zero.  Over the more than 12 months that elapsed between her initial and follow-up 
interview, Amy continued to receive her preferred catheters and no bill from her supplier. 
Amy’s EOB showed that the supplier is being reimbursed 80% of what the insurer agreed to 
pay the supplier, with the consumer responsible for the remaining 20%, for which the supplier, 
month after month, declined to bill. The supplier explained the business approach to catheter 
fulfillment that, ideally, addresses consumer catheter preference while minimizing their 
financial burden.  
 
I rarely have any patients who are really paying anything for their catheters. 
For all commercial insurance, we send the catheters to the person, but we only 
bill the primary commercial insurance carrier, and then we don’t charge the 
co-pay.  [However], if your insurance is paying a dollar, and it cost us a dollar 
fifty to buy that catheter, we can’t send it to you for a dollar. So, we may say, 
“Look if you can make up the difference in the cost of the catheter and the 
shipping, we are good. We might also say, “Would you be open to us sending 
you some other samples?”  Most of the time, people are open to saying, “Oh, 
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Discussion 
 
Five inhibitors and four enablers emerged from our stakeholders’ experience of the 
catheter reimbursement network. They are discussed below, touching on their amenability to 
change. 
 
Inhibitor1. Paucity of reimbursement codes, failure to differentiate HCs from uncoated ICs  
 
As our disability advocate indicated, manufacturers have petitioned CMS multiple 
times to expand IC coding to create differential coding for HCs. Expert testimony presented 
reiterated the UTI reduction literature already cited using HCs. In one particular petition 
(Centers for Medicare and Medicaid Services, 2014) “work-around coding” has already been 
adopted by “many state Medicaid and private insurance agencies” (p. 23). CMS denied this 
petition, stating that the current codes were adequate, and the codes remain unchanged. Those 
with NB whose access to catheters depend on reimbursement falling within the CMS payment 
schedule that fail to establish a higher rate for HCs effectively inhibits access to a demonstrably 
safer product. Further, there is a large amount of evidence showing the cost-effectiveness of 
HCs in the health systems of such countries as Brazil (Truzzi et al., 2018), Canada (Welk et 
al., 2018), Italy (Rognoni & Tarricone, 2017), and Japan (Watanabe et al., 2017) due to 
associated reduction in UTI burden. We could find no similar study in the US system and no 
data on the number of individuals who would switch to HCs if reimbursement coding 
expanded. Worth mentioning is that one third (two out of six) of our consumers preferred using 
basic uncoated IC. Though this sample is very small, it suggests that not every person with NB 
would opt for HCs if reimbursement were liberalized. 
 
Inhibitor 2. Opacity of private insurance  
 
This topic was touched on very briefly but dramatically in the case of Amy who had to 
select an insurance plan without full information on the actual cost of her ICs. Lack of 
transparency of final, health service cost is a by-product of private, commercial negotiations 
among the parties to private insurance. It touches all insured health services, not just ICs, and 
does not seem amenable to change in the near future. 
 
Inhibitor 3. Need to document recurring UTI to be eligible for hydrophilic catheters and closed 
catheters 
  
The webpage presenting the US Surgeon General’s Priorities for Health and the 
Economy (US Surgeon General, 2018) declares that, “It is widely accepted among public health 
and medical experts that it is more cost effective to invest in preventive measures that foster 
health and well-being rather than treating the manifestations of poor health.” (para. 2)  The 
need to experience two UTI to gain access to technology that prevents UTI is a policy in stark 
contrast to the Surgeon General’s declaration. A diagnosis of NB should be adequate to secure 
reimbursement of lower risk ICs, both HCs and closed catheters. 
The reimbursement code wording, “sterile” versus “closed,” ignores how the 
technology functions not just to help individuals empty their bladders (a physiological 
function), but to help them, particularly women, move freely and participate in a world (social 
function). Two prior studies of ICs similarly identified lack of accessible (and acceptable) 
bathrooms and, for women, positioning to cath, to be the most prevalent problems reported 
(Bolinger & Engberg, 2013; Wilde, Brasch, & Zhang, 2011). 
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The CMS Medicare-Medicaid Coordination Office disseminates a Disability-
Competent-Care (DCC) Self-Assessment Tool (Resources for Integrated Care, 2017) to help 
health plans and systems evaluate their implementation of the DCC model. DCC recognizes 
the whole person, responding to an individual’s “physical and clinical needs while considering 
his or her emotion, social, intellectual, and spiritual needs” (p. 3). In the spirit of DCC, the 
catheter is not just a urological device allowing a person with NB to empty his/her bladder, it 
is technology that facilitates access to life activity on par with those enjoyed by people who 
void without catheters. Focusing eligibility for reimbursement solely on UTI prevention 
neglects the similarly important psychosocial function of closed ICs. CMS includes the DCC 
tool on their website suggesting the potential ability to use the DCC to expand closed system 
reimbursement.  
 
Inhibitor 4. 200 catheter per month cap 
 
Payer rules relative to the flow of catheters, restrict shipments to one per month and cap 
standard allotments to 200 catheters per month, threaten catheter security for consumers. Our 
consumers addressed this problem through conservation and leverage of OTC ICs. No 
explanation was found in federal records as to the rationale for capping ICs at the specific level 
of 200 per month when CMS eliminated the requirement to reuse ICs in 2008. Our stakeholder 
experiences suggest the current cap of 200 ICs is too low and should be changed, or that an 
explicit provision to establish a “catheter security cushion” should be established. Given the 
exceptions made in the private and VA systems, an increased number may be feasible. 
 
Inhibitor 5. Lack of discernment among consumers relative to catheters 
 
When a consumer, as was Don’s experience, recognizes there is a problem with a 
catheter, it is likely to get addressed. If, on the other hand, a consumer is using a suboptimal 
catheter that is not generating problems at the threshold of awareness, there is no mechanism 
to trigger shifting over to better technology. Manufacturers and suppliers have the information 
that consumers need and some seek out, but there is no neutral and objective mechanism 
currently providing a clearinghouse. Disability advocates are perhaps best positioned to help 
consumers find and evaluate catheter information. 
 
Enabler 1. Negotiability of private insurance plans between insurers and corporate purchasers 
 
The employer is potentially a powerful ally to a consumer/employee in receiving 
desired IC reimbursement by virtue of the employer's client relationship with the private 
insurer. The potential benefit may depend on the value the employer places on the individual 
employee, and the employer’s willingness to advocate. Appealing to one’s employer in a 
dispute with insurance is a strategy that employees with NB should, however, be aware. Due 
to protected health information5 and concerns about potential discrimination at work6 
consumers may understandably want to keep their personal medical needs private.  
Enabler 2. IC variety 
 
5 Health Insurance Portability and Accountability Act of 1996. HIPAA gives consumers rights over their own 
health information. https://www.hhs.gov/hipaa/for-individuals/index.html, accessed 9/10/2018. 
6 The Rehabilitation Act of 1973 prohibits discrimination on the basis of disability in programs conducted 
by Federal agencies, in programs receiving Federal financial assistance, in Federal employment and in the 
employment practices of Federal contractors.  The Americans with Disabilities Act of 1990 prohibits private sector 
employers who employ 15 or more individuals and all State and local government employers from discriminating 
against qualified individuals with disabilities in all aspects of employment. discrimination.   
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Wider choice of ICs suggests that more people with NB will be able to find a catheter 
that suits their needs and desires. The lucrative European market may serve as an impetus for 
innovation of new technology with the result that consumers in the US ultimately benefit from. 
Lack of knowledge of catheters limits the potential benefits of increasing IC variety. 
 
Enabler 3. OTC availability of basic straight catheters 
 
An extremely important enabler of well-being in people with NB is the ability to buy 
ICs OTC, giving consumers control over their fundamental ability to cath. OTC availability 
offsets the negative effects of a number cap on ICs reimbursed each month that does not 
fluctuate to meet individuals’ changing life situations. Though sale of OTC ICs is a 
commonplace, the legality of the practice, in retail outlets in jurisdictions across the US or 
online is unclear. Lack of legal clarity undermines the solidity of this catheter security strategy.  
 
Enabler 4. Centrality of the supplier 
 
Our expectation in this study was that various payers, particularly insurers in the 
commercial space, would have catheter reimbursement policies that directly impacted 
consumer satisfaction and well-being. This scenario did not play out in the network described 
by our small group of participants. Rather, the supplier emerged as the actor positioned to make 
the wheels of the catheter acquisition process turn. Our participants described a functioning 
(though not without problems) catheter distribution system where suppliers and manufacturers 
were able to provide products and services. Products and services are then reimbursed by 
payers, both public and private, while satisfying consumer preference and demand for catheters 
with no out-of-pocket cost (e.g., absorbing co-pays). Though not the experience of our 
stakeholders, there are risks inherent in the central position the supplier holds in the IC 
distribution process. Particularly in the absence of an objective source of information to 
compare IC products. Beatrice’s narrative demonstrating her supplier’s attentiveness could also 
be interpreted as describing a supplier whose interest was to increase her profit by offering 
Beatrice a cheaper product or acting on an incentive from a manufacturer to give a certain 
product more exposure. Of course, both narratives can simultaneously apply. Beatrice’s 
supplier can be motivated both by recognition of her client’s possible need of a better product 
and a desire to increase profit. Again, creation of an information clearinghouse to help 




Our study has several limitations. The sample of nine stakeholders is small. Participants 
were drawn from all the principal categories of actors identified with the US IC reimbursement 
ecosystem, however their experiences create a roughly-sketched view of just one possible 
network of people, things, and abstractions governing IC reimbursement. A different sample 
of individuals might present a differently configured network. The uniformly high degree of 
self-efficacy, passion, and strength of self-advocacy skills among our participants may have 
led to their predominantly good outcomes. For consumers with fewer personal and material 
resources, the outcomes may have looked different. Notably, we did not interview anyone 
whose catheters were primarily provided through Medicaid. Perspectives and observations 
described in this article reflect peoples’ personal interpretation of their experiences and may or 
may not be objectively correct. No participant had experience with the third main category 
(code) for reimbursement, namely, coudé catheters. 
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Conclusions and Recommendations 
 
Differentiation of HCs, or coated ICs more generically, is supported by the literature 
and would seem to be a reform whose time has come. Requiring people with NB to experience 
two UTIs before having access to UTI-preventing ICs disagrees with the general population 
perspective on illness prevention and antibiotic therapy minimization. Further, these current 
eligibility criteria neglect the psychosocial importance of closed catheters, especially for 
women aligned with principles of Disability-Competent-Care. Persons with NB, already at 
high risk for UTI, should be eligible for the HC and closed systems if they prefer without 
having to first experience life-threatening illness. Monthly allocation of catheters should be 
individualized and the creation of a back-up supply allowed. The OTC availability of ICs is an 
important source of catheter security and provides individuals control over emptying their 
bladders that should continue. Information on current and emerging catheter technologies 
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